https://sputnikglobe.com/20211127/gamaleya-center-says-covid-19-antibody-drug-will-not-be-available-earlier-than-late-2022-1091071471.html
Gamaleya Center Says COVID-19 Antibody Drug Will Not Be Available Earlier Than Late 2022
Gamaleya Center Says COVID-19 Antibody Drug Will Not Be Available Earlier Than Late 2022
Sputnik International
PETROPAVLOVSK-KAMCHATSKIY, Russia (Sputnik) - The antibody treatment against COVID-19 from Russia's Gamaleya National Research Center of Epidemiology will... 27.11.2021, Sputnik International
2021-11-27T16:21+0000
2021-11-27T16:21+0000
2021-11-27T16:21+0000
russia
gamaleya research institute of epidemiology and microbiology
covid-19
https://cdn1.img.sputnikglobe.com/img/105323/44/1053234484_0:96:1921:1176_1920x0_80_0_0_f84a815947d7ac5fdedb6050fd10384e.jpg
"It appears that this medicine will see the light of day at best at the end of the coming year and not in the beginning," Gintsburg told Russian broadcaster Rossiya 1.Earlier in the month, Gintsburg said that the center would begin the drug's clinical trials next January and expected to be completed within 3-4 months.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
gamaleya research institute of epidemiology and microbiology, covid-19
gamaleya research institute of epidemiology and microbiology, covid-19
Gamaleya Center Says COVID-19 Antibody Drug Will Not Be Available Earlier Than Late 2022
PETROPAVLOVSK-KAMCHATSKIY, Russia (Sputnik) - The antibody treatment against COVID-19 from Russia's Gamaleya National Research Center of Epidemiology will become available no earlier than late 2022, Alexander Gintsburg, the center's director, said on Saturday.
"It appears that this medicine will see the light of day at best at the
end of the coming year and not in the beginning," Gintsburg told Russian broadcaster Rossiya 1.
Earlier in the month, Gintsburg said that the center would begin the
drug's clinical trials next January and expected to be completed within 3-4 months.
